National Academies Press: OpenBook
« Previous: 13 Creating an Evidence-Based Blueprint for Action
Suggested Citation:"References." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×

References

Ahuja, S. D., D. Ashkin, M. Avendano, R. Banerjee, M. Bauer, J. N. Bayona, M. C. Becerra, A. Benedetti, M. Burgos, R. Centis, E. D. Chan, C. Y. Chiang, H. Cox, L. D’Ambrosio, K. DeRiemer, N. H. Dung, D. Enarson, D. Falzon, K. Flanagan, J. Flood, M. L. Garcia-Garcia, N. Gandhi, R. M. Granich, M. G. Hollm-Delgado, T. H. Holtz, M. D. Iseman, L..G. Jarlsberg, S. Keshavjee, H.-R. Kim, W.-J. Koh, J. Lancaster, C. Lange, W. C. M. de Lange, V. Leimane, C. C. Leung, J. Li, D. Menzies, G. B. Migliori, S. P. Mishustin, C. D. Mitnick, M. Narita, P. O’Riordan, M. Pai, D. Palmero, S.-K. Park, G. Pasvol, J. Pena, C. Perez-Guzman, M.I.D. Quelapio, A. Ponce-de-Leon, V. Riekstina, J. Robert, S. Royce, H. S. Schaaf, K. J. Seung, L. Shah, T..S. Shim, S. S. Shin, Y. Shiraishi, J. Sifuentes-Osornio, G. Sotgiu, M. J. Strand, P. Tabarsi, T. E. Tupasi, R. van Altena, M. Van der Walt, T. S. Van der Werf, M. H. Vargas, P. Viiklepp, J. Westenhouse, W. W. Yew, and J.-J. Yim, on behalf of the Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB. 2012. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: An individual patient data meta-analysis of 9,153 patients. PLoS Medicine 9(8):e1001300.

Akachi, Y., A. Zumla, and R. Atun. 2012. Investing in improved performance of national tuberculosis programs reduces the tuberculosis burden: Analysis of 22 high-burden countries, 2002–2009. Journal of Infectious Diseases 205(Suppl 2): S284–S292.

Aksenova, V. A. 2013. Status of pediatric MDR/XDR TB in the Russian Federation. Presentation at the IOM workshop on the Global Crisis of Drug-Resistant Tuberculosis and the Leadership of the BRICS Countries: Challenges and Opportunities, January 16–18, Beijing, China.

Alisjahbana, B., E. Sahiratmadja, E. J. Nelwan, A. M. Purwa, Y Ahmad, T. H. Ottenhoff, R. H. Nelwan, I. Parwati, J. W. van der Meer, R. van Crevel. 2007. The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis. Clinical Infectious Diseases 45(4):428–435.

Andrews, J, R., N. S. Shah, N. Gandhi, T. Moll, G. Friedland, and the Tugela Ferry Care and Research (TF CARES) Collaboration. 2007. Multidrug-resistant and extensively drug-resistant tuberculosis: Implications for the HIV epidemic and antiretroviral therapy rollout in South Africa. Journal of Infectious Diseases 196(Suppl 3): S482–S490.

Suggested Citation:"References." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×

Becerra, M. C., S. C. Appleton, M. F. Franke, K. Chalco, F. Arteaga, J. Bayona, M. Murray, S. S. Atwood, and C. D. Mitnick. 2011. Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: A retrospective cohort study. Lancet 377(9760):147–152.

Being brave: Stories of children with drug-resistant tuberculosis. 2012. The Sentinel Project for Pediatric Drug-Resistant Tuberculosis. http://sentinelproject.files.wordpress.com/2012/03/stories-of-children-with-dr-tb2.pdf (accessed April 15, 2013).

Blanc, F. X., T. Sok, D. Laureillard, L. Borand, C. Rekacewicz, E. Nerrienet, Y. Madec, O. Marcy, S. Chan, N. Prak, C. Kim, K. K. Lak, C. Hak, B. Dim, C. I. Sin, S. Sun, B. Guillard, B. Sar, S. Vong, M. Fernandez, L. Fox, J. F. Delfraissy, A. E. Goldfeld, and the CAMELIA (ANRS 1295–CIPRA KH001) Study Team. 2011. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. New England Journal of Medicine 365(16):1471–1481.

Boccia, D., J. Hargreaves, K. Lonnroth, E. Jaramillo, J. Weiss, M. Uplekar, J. D. Porter, and C. A. Evans. 2011. Cash transfer and microfinance interventions for tuberculosis control: Review of the impact evidence and policy implications. International Journal of Tuberculosis and Lung Disease 15(Suppl 2): S37–S49.

Böttger, E. C. 2011. The ins and outs of Mycobacterium tuberculosis drug susceptibility testing. Clinical Microbiology and Infection 17(8):1128–1134.

Cegielski, P., P. Nunn, E. V. Kurbatova, K. Weyer, T. L. Dalton, D. F. Wares, M. F. Iademarco, K. G. Castro, and M. Raviglione. 2012. Challenges and controversies in defining totally drug-resistant tuberculosis. Emerging Infectious Diseases 18(11):e2.

Chaisson, R. E. 2013. Addressing the spectrum of drug-resistant TB: Clinical perspective. Presentation at the IOM workshop on the Global Crisis of Drug-Resistant Tuberculosis and the Leadership of the BRICS Countries: Challenges and Opportunities, January 16–18, Beijing, China.

Chen, M. 2013. Programmatic management of MDR-TB in China: Progress, plan and challenge. Presentation at the IOM workshop on the Global Crisis of Drug-Resistant Tuberculosis and the Leadership of the BRICS Countries: Challenges and Opportunities, January 16–18, Beijing, China.

Cohen, T., M. Murray, K. Wallengren, G. G. Alvarez, E. Y. Samuel, and D. Wilson. 2010. The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in KwaZulu-Natal, South Africa: A postmortem study. PLoS Medicine 7(6).

Comas, I., and S. Gagneux. 2009. The past and future of tuberculosis research. PLoS Pathogens 5(10):e1000600.

Comas, I., S. Borrell, A. Roetzer, G. Rose, B. Malla, M. Kato-Maeda, J. Galagan, S. Niemann, and S. Gagneux. 2011. Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nature Genetics 44(1):106–110.

Dalton, T., P. Cegielski, S. Akksilp, L. Asencios, J. Campos Caoili, S. N. Cho, V. V. Erokhin, J. Ershova, M. T. Gler, B. Y. Kazennyy, H. J. Kim, K. Kliiman, E. Kurbatova, C. Kvasnovsky, V. Leimane, M. van der Walt, L. E. Via, G. V. Volchenkov, M. A. Yagui, H. Kang, and the Global PETTS Investigators. 2012. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: A prospective cohort study. Lancet 380(9851):1406–1417.

Deng, Y., Y. Wang, J. Wang, H. Jing, C. Yu, H. Wang, Z. Liu, E. A. Graviss, and X. Ma. 2011. Laboratory-based surveillance of extensively drug-resistant tuberculosis, China. Emerging Infectious Diseases 17(3):495–497.

Devaux, I., K. Kremer, H. Heersma, and D. Van Soolingen. 2009. Clusters of multidrug-resistant Mycobacterium tuberculosis cases, Europe. Emerging Infectious Diseases 15(7):1052–1060. http://wwwnc.cdc.gov/eid/article/15/7/08-0994.htm (accessed November 25, 2013).

Suggested Citation:"References." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×

Dooley, K. E., T. Tang, J. E. Golub, S. E. Dorman, and W. Cronin. 2009. Impact of diabetes mellitus on treatment outcomes of patients with active tuberculosis. American Journal of Tropical Medicine and Hygiene 80(4):634–639.

Dye, C., B. G. Williams, M. A. Espinal, and M. C. Raviglione. 2002. Erasing the world’s slow stain: Strategies to beat multidrug-resistant tuberculosis. Science 295(5562):2042–2046.

Ettehad, D., Schaaf, H. S., Seddon, J. A., Cooke, G. S., and N. Ford. 2012. Treatment outcomes for children with multidrug-resistant tuberculosis: A systematic review and metaanalysis. Lancet Infectious Diseases 12:449–456.

Farmer, P. 2013. Drug-resistant tuberculosis: What have we learned? Presentation at the IOM workshop on the Global Crisis of Drug-Resistant Tuberculosis and the Leadership of the BRICS Countries: Challenges and Opportunities, January 16–18, Beijing, China.

Farmer, P. E., C. T. Nutt, C. M. Wagner, C. Sekabaraga, T. Nuthulaganti, J. L. Weigel, D. B.

Farmer, A. Habinshuti, S. D. Mugeni, J. C. Karasi, and P. C. Drobac. 2013. Reduced premature mortality in Rwanda: Lessons from success. British Medical Journal 346:f65.

Fitzpatrick, C., and K. Floyd K. 2012. A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis. Pharmacoeconomics 30(1):63–80.

Fox, G. J., S. E. Barry, W. J. Britton, and G. B. Marks. 2013. Contact investigation for tuberculosis: A systematic review and meta-analysis. European Respiratory Journal 41(1):140–156.

Frieden, T. R., P. I. Fujiwara, R. M. Washko, and M. A. Hamburg. 1995. Tuberculosis in New York City—turning the tide. New England Journal of Medicine 333(4):229–233.

Gelmanova, I. Y., S. Keshavjee, V. T. Golubchikova, V. I. Berezina, A. K. Strelis, G. V. Yanova, S. Atwood, and M. Murray. 2007. Barriers to successful tuberculosis treatment in Tomsk, Russian Federation: Non-adherence, default and the acquisition of multidrug resistance. Bulletin of the World Health Organization 85(9):703–711.

Hanrahan, C. F., S. E. Dorman, L. Erasmus, H. Koornhof, G. Coetzee, and J. E. Golub. 2012. The impact of expanded testing for multidrug resistant tuberculosis using geontype MTBDRplus in South Africa: An observational cohort study. PLoS One 7(11):e49898.

He, G. X., Y. G. Xie, L. X. Wang, M. W. Borgdorff, M. J. van der Werf, J. H. Fan, X. L. Yan, F. B. Li, X. Z. Zhang, Y. L. Zhao, and S. van den Hof. 2010. Follow-up of patients with multidrug resistant tuberculosis four years after standardized first-line drug treatment. PLoS One 5(5):e10799.

Henter, J. I., K. Palmkvist-Kaijser, B. Holzgraefe, Y. T. Bryceson, and K. Palmer. 2010. Cytotoxic therapy for severe swine flu A/H1N1. Lancet 376(9758):2116.

IOM (Institute of Medicine). 2009. Addressing the threat of drug-resistant tuberculosis: A realistic assessment of the challenge: Workshop summary. Washington, DC: The National Academies Press.

IOM. 2011a. The emerging threat of drug-resistant tuberculosis in Southern Africa: Global and local challenges and solutions: Summary of a joint workshop. Washington, DC: The National Academies Press.

IOM. 2011b. The new profile of drug-resistant tuberculosis in Russia: A global and local perspective: Summary of a joint workshop. Washington, DC: The National Academies Press.

IOM. 2012. Facing the reality of drug-resistant tuberculosis in India: Challenges and potential solutions: Summary of a joint workshop. Washington, DC: The National Academies Press.

IOM. 2013. Developing and strengthening the global supply chain for second-line drugs for multidrug-resistant tuberculosis: Workshop summary. Washington, DC: The National Academies Press.

Joshi, R., A. L. Reingold, D. Menzies, and M. Pai. 2006. Tuberculosis among health-care workers in low- and middle-income countries: A systematic review. PLoS Medicine 3(12):e494.

Suggested Citation:"References." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×

Keshavjee, S. 2013. Turning the tide: The impact of high quality care delivery on the epidemiology of tuberculosis in Tomsk, Russian Federation. Presentation at the IOM workshop on the Global Crisis of Drug-Resistant Tuberculosis and the Leadership of the BRICS Countries: Challenges and Opportunities, January 16–18, Beijing, China.

Keshavjee, S., and K. Seung. 2008. Stemming the tide of multidrug-resistant tuberculosis: Major barriers to addressing the growing epidemic. http://www.iom.edu/~/media/Files/Activity%20Files/Research/DrugForum/IOM_MDRTB_whitepaper_2009_01_14_FINAL_Edited.pdf (accessed October 3, 2013).

Li, L., Y. Lin, F. Mi, S. Tan, B. Liang, C. Guo, L. Shi, L. Liu, F. Gong, Y. Li, J. Chi, R. Zachariah, A. Kapur, K. Lönnroth, and A. D. Harries. 2012. Screening of patients with tuberculosis for diabetes mellitus in China. Tropical Medicine and International Health 17:1294–1301.

Li, X., Y. Zhang, X. Shen, G. Shen, X. Gui, B. Sun, J. Mei, K. DeRiemer, P. M. Small, and Q. Gao. 2007. Transmission of drug-resistant tuberculosis among treated patients in Shanghai, China. Journal of Infectious Diseases 195(6):864–869.

Lin, Y., L. Li, F. Mi, J. Du, Y. Dong, Z. Li, W. Qi, X. Zhao, Y. Cui, F. Hou, R. Zachariah, A. Kapur, K. Lönnroth, and A. D. Harries. 2012. Screening patients with diabetes mellitus for tuberculosis in China. Tropical Medicine and International Health 17:1302–1308.

Louw, G. E., R. M. Warren, N. C. Gey van Pittius, R. Leon, A. Jimenez, R. Hernandez-Pando, C. R. McEvoy, M. Grobbelaar, M. Murray, P. D. van Helden, and T. C. Victor. 2011. Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux. American Journal of Respiratory and Critical Care Medicine 184(2):269–276.

Loveday M., N. Padayatchi, A. Voce, J. Brust, and K. Wallengren. 2013. Is the MDR-TB patient journey in South Africa patient centred? International Journal of Tuberculosis and Lung Disease 17(10): S56–S59.

Management of drug-resistant tuberculosis in children: A field guide. 2012. The Sentinel Project for Pediatric Drug-Resistant Tuberculosis and USAID. http://sentinelproject.files.wordpress.com/2012/11/sentinel_project_field_guide_2012.pdf (accessed April 15, 2013).

Meacci, F., G. Orrù, E. Iona, F. Giannoni, C. Piersimoni, G. Pozzi, L. Fattorini, and M. R. Oggioni. 2005. Drug resistance evolution of a Mycobacterium tuberculosis strain from a noncompliant patient. Journal of Clinical Microbiology 43(7):3114–3120.

Menzies, D., R. Joshi, and M. Pai. 2007. Risk of tuberculosis infection and disease associated with work in health care settings. International Journal of Tuberculosis and Lung Disease 11(6):593–605.

Mitnick, C., J. Bayona, E. Palacios, S. Shin, J. Furin, F. Alcántara, E. Sánchez, M. Sarria, M. Becerra, M. C. Fawzi, S. Kapiga, D. Neuberg, J. H. Maguire, J. Y. Kim, and P. Farmer. 2003. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. New England Journal of Medicine 348(2):119–128.

Morsy, A. M., H. H. Zaher, M. H. Hassan, and A. Shouman. 2003. Predictors of treatment failure among tuberculosis patients under DOTS strategy in Egypt. Eastern Mediterranean Health Journal 9(4):689–701.

Muthuswamy, P., T. C. Hu, B. Carasso, M. Antonio, and N. Dandamudi. 1995. Prednisone as adjunctive therapy in the management of pulmonary tuberculosis—Report of 12 cases and review of the literature. Chest 107(6):1621–1630.

Naidoo, S., and C. C. Jinabhai. 2006. TB in health care workers in KwaZulu-Natal, South Africa. International Journal of Tuberculosis and Lung Disease 10(6):676–682.

NIAID (National Institute of Allergy and Infectious Diseases) Working Group. 2007. NIAID Research Agenda: Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis. Bethesda, MD: National Institute of Allergy and Infectious Diseases.

Suggested Citation:"References." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×

Nijland, H. M., R. Ruslami, J. E. Stalenhoef, E. J. Nelwan, B. Alisjahbana, R. H. Nelwan, A. J. van der Ven, H. Danusantoso, R. E. Aarnoutse, and R. van Crevel. 2006. Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clinical Infectious Diseases 43(7):848–854.

O’Donnell, M. R., J. Jarand, M. Loveday, N. Padayatchi, J. Zelnick, L. Werner, K. Naidoo, I. Master, G. Osburn, C. Kvasnovsky, K. Shean, M. Pai, M. van der Walt, D. R. Horsburgh, and K. Dheda. 2010. High incidence of hospital admissions with multidrug-resistant and extensively drug-resistant tuberculosis among South African health care workers. Annals of Internal Medicine 153(8):516–522.

Oursler, K. K., R. D. Moore, W. R. Bishai, S. M. Harrington, D. S. Pope, and R. E. Chaisson. 2002. Survival of patients with pulmonary tuberculosis: Clinical and molecular epidemiologic factors. Clinical Infectious Diseases 34(6):752–759.

Padayatchi, N., S. Bamber, H. Dawood, and R. Bobat. 2006. Multidrug-resistant tuberculous meningitis in children in Durban, South Africa. Pediatric Infectious Disease Journal 25(2):147–150.

Pym, A. S., B. Saint-Joanis, and S. T. Cole. 2002. Effect of katG mutations on the virulence of Mycobacterium tuberculosis and the implication for transmission in humans. Infection and Immunity 70(9):4955–4960.

Rich, M. L., A. C. Miller, P. Niyigena, M. F. Franke, J. B. Niyonzima, A. Socci, P. C. Drobac, M. Hakizamungu, A. Mayfield, R. Ruhayisha, H. Epino, S. Stulac, C. Cancedda, A. Karamaga, S. Niyonzima, C. Yarbrough, J. Fleming, C. Amoroso, J. Mukherjee, M. Murray, P. Farmer, and A. Binagwaho. 2012. Excellent clinical outcomes and high retention in care among adults in a community-based HIV treatment program in rural Rwanda. Journal of Acquired Immune Deficiency Syndromes 59(3):e35–e42.

Riley, R. L., C. Mills, and W. Nyka. 1959. Aerial dissemination of tuberculosis—a two year study of contagion on a tuberculosis ward. American Journal of Hygiene 70:185–196.

Salvo, F., K. Dorjee, K. Dierberg, G. Delaco, C. Rodrigues, R. E. Chaisson, T. Dorji Sadutshang, and D. M. Cirillo. 2012. Drug resistance survey among Tibetan refugees in India. Abstract PC-447-16 presented at the 43rd Union World Conference on Lung Health, 13–17 November, Kuala Lumpur, Malaysia.

Seddon, J. A., D. H. Visser, M. Bartens, A. M. Jordaan, T. C. Victor, A. M. van Furth, J. F. Schoeman, and H. S. Schaaf. 2012a. Impact of drug resistance on clinical outcome in children with tuberculous meningitis. Pediatric Infectious Disease Journal 31(7):711–716.

Seddon, J. A., J. J. Furin, M. Gale, H. Del Castillo Barrientos, R. M. Hurtado, F. Amanullah, N. Ford, J. R. Starke, and H. S. Schaaf. The Sentinel Project on Pediatric Drug-Resistant Tuberculosis. 2012b. Caring for children with drug-resistant tuberculosis: Practice-based recommendations. American Journal of Respiratory and Critical Care Medicine 186(10):953–964.

Seddon, J. A., Perez-Velez, C. M., Schaaf, H. S., Furin, J. J., Marais, B. J., Tebruegge, M., Detjen, A., Hesseling, A. C., Shah, S., Adams, L. V., Starke, J. R., Swaminathan, S., and M. Becerra on behalf of The Sentinel Project on Pediatric Drug-Resistant Tuberculosis. 2013. Consensus statement on research definitions for drug-resistant tuberculosis in children. Journal of the Pediatric Infectious Diseases Society 2(2):100–109.

Sentinel Project on Pediatric Drug-Resistant Tuberculosis. 2013. http://sentinel-project.org (accessed July 29, 2013).

Shen, G., Z. Xue, X. Shen, B. Sun, X. Gui, M. Shen, J. Mei, and Q. Gao. 2006. The study recurrent tuberculosis and exogenous reinfection, Shanghai, China. Emerging Infectious Diseases 12(11):1776–1778.

Suggested Citation:"References." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×

Siu, G. K., Y. Zhang, T. C. Lau, R. W. Lau, P. L. Ho, W. W. Yew, S. K. Tsui, V. C. Cheng, K. Y. Yuen, and W. C. Yam. 2011. Mutations outside the rifampicin resistance-determining region associated with rifampicin resistance in Mycobacterium tuberculosis. Journal of Antimicrobial Chemotherapy 66(4):730–733.

Skrahina, A., H. Hurevich, A. Zalutskaya, E. Sahalchyk, A. Astrauko, W. van Gemert, S. Hoffner, V. Rusovich, and M. Zignol. 2012. Alarming levels of drug-resistant tuberculosis in Belarus: Results of a survey in Minsk. European Respiratory Journal 39(6):1425–1431.

Small, P. M., R. W. Shafer, P. C. Hopewell, S. P. Singh, M. J. Murphy, E. Desmond, M. F. Sierra, and G. K. Schoolnik. 1993. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. New England Journal of Medicine 328(16):1137–1144.

Sonnenberg, P., J. Murray, J. R. Glynn, S. Shearer, B. Kambashi, and P. Godfrey-Faussett. 2001. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: A cohort study in South African mineworkers. Lancet 358(9294):1687–1693.

Stuckler, D., S. Basu, M. McKee, and L. King. 2008. Mass incarceration can explain population increases in TB and multidrug-resistant TB in European and central Asian countries. Proceedings of the National Academy of Sciences of the United States of America 105(36):13280–13285.

Takahashi, T., M. Tamura, and T. Takasu. 2012. The PCR-based diagnosis of central nervous system tuberculosis: Up to date. Tuberculosis Research and Treatment 2012:831292.

Tobin, D. M., F. J. Roca, S. F. Oh, R. McFarland, T. W. Vickery, J. P. Ray, D. C. Ko, Y. Zou, N. D. Bang, T. T. Chau, J. C. Vary, T. R. Hawn, S. J. Dunstan, J. J. Farrar, G. E. Thwaites, M. C. King, C. N. Serhan, and L. Ramakrishnan. 2012. Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell 148(3):434–446.

Torok, M. E., T. T. Chau, P. P. Mai, N. D. Phong, N. T. Dung, L. V. Chuong, S. J. Lee, M. Caws, M. D. de Jong, T. T. Hien, and J. J. Farrar. 2008. Clinical and microbiological features of HIV-associated tuberculous meningitis in Vietnamese adults. PLoS ONE 3(3):e1772.

Treatment Action Group. 2012. Tuberculosis Research & Development: 2012 Report on Tuberculosis Research Funding Trends, 2005–2011. http://www.treatmentactiongroup.org/tbrd2012 (accessed July 29, 2013).

Udwadia, Z. F., R. A. Amale, K. K. Ajbani, and C. Rodrigues. 2012. Totally drug-resistant tuberculosis in India. Clinical Infectious Diseases 54(4):579–581.

United Nations. 2012. Millennium Development Goal 8: The Global Partnership for Development: Making Rhetoric a Reality. MDG Gap Task Force 2012. http://www.who.int/medicines/mdg/mdg8report2012_en.pdf. (accessed October 3, 2013).

Velayati, A. A., M. R. Masjedi, P. Farnia, P. Tabarsi, J. Ghanavi, A. H. Ziazarifi, and S. E. Hoffner. 2009. Emergence of new forms of totally drug-resistant tuberculosis bacilli: Super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest 136(2):420–425.

Vella, V., V. Racalbuto, R. Guerra, C. Marra, A. Moll, Z. Mhlanga, M. Maluleke, H. Mhlope, B. Margot, G. Friedland, N. S. Shah, and N. R. Gandhi. 2011. Household contact investigation of multidrug-resistant and extensively drug-resistant tuberculosis in a high HIV prevalence setting. International Journal of Tuberculosis and Lung Disease 15(9):1170–1175.

Volchenkov, G. V. 2013. Institutional infection control in Russia. Presentation at the IOM workshop on the Global Crisis of Drug-Resistant Tuberculosis and the Leadership of the BRICS Countries: Challenges and Opportunities, January 16–18, Beijing, China.

Suggested Citation:"References." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×

Volchenkov, G. V., L. D. Drobasheva, E. V. Putova, V. A. Puzanov, I. D. Danilova, and H. Kluge. 2004. [Implementation of a programme for detection and treatment of patients with tuberculosis in the Vladimir Region.] Problemy Tuberkuleza I Boleznei Legkikh (8):21–22.

Wallengren, K., F. Scano, P. Nunn, B. Margot, S. S. Buthelezi, B. Williams, A. Pym, E. Y. Samuel, F. Mirzayev, W. Nkhoma, L. Mvusi, and Y. Pillay. 2011. Drug-resistant tuberculosis, KwaZulu-Natal, South Africa, 2001-2007. Emerging Infectious Diseases 17(10):1913–1916.

Wallis, R. S. 2005. Reconsidering adjuvant immunotherapy for tuberculosis. Clinical Infectious Diseases 41(2):201–208.

We can heal: Prevention, diagnosis, treatment, care, and support: Addressing drug-resistant tuberculosis in children. 2013. The Sentinel Project for Pediatric Drug-Resistant Tuberculosis and Treatment Action Group. http://www.treatmentactiongroup.org/sites/tagone.drupalgardens.com/files/201303/tag-we-can-heal-final-sm_0.pdf (accessed April 15. 2013).

WHO (World Health Organization). 2008. Guidelines for the programmatic management of drug-resistant tuberculosis: Emergency update 2008. http://whqlibdoc.who.int/publications/2008/9789241547581_eng.pdf (accessed July 29, 2013).

WHO. 2010. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. Geneva: WHO Press. http://whqlibdoc.who.int/publications/2010/9789241599191_eng.pdf (accessed April 16, 2013).

WHO. 2012. Global tuberculosis report 2012. http://apps.who.int/iris/bitstream/10665/75938/1/9789241564502_eng.pdf (accessed November 11, 2013).

WHO and The Union. 2011. Collaborative framework for care and control of tuberculosis and diabetes. Geneva: World Health Organization.

Willingham, F. F., T. L. Schmitz, M. Contreras, S. E. Kalangi, A. M. Vivar, L. Caviedes, E. Schiantarelli, P. M. Neumann, C. Bern, R. H. Gilman, and the Working Group on TB in Peru. 2001. Hospital control and multidrug-resistant pulmonary tuberculosis in female patients, Lima, Peru. Emerging Infectious Diseases 7(1):123–127.

Yang, W., J. Lu, J. Weng, W. Jia, L. Ji, J. Xiao, Z. Shan, J. Liu, H. Tian, Q. Ji, D. Zhu, J. Ge, L. Lin, L. Chen, X. Guo, Z. Zhao, Q. Li, Z. Zhou, G. Shan, J. He, and the China National Diabetes and Metabolic Disorders Study Group. 2010. Prevalence of diabetes among men and women in China. New England Journal of Medicine 362(12):1090–1101.

Yuen, C. M., A. W. Tolman, T. Cohen, J. B. Parr, S. Keshavjee, and M. C. Becerra. 2013. Isoniazid-resistant tuberculosis in children: A systematic review. Pediatric Infectious Disease Journal 32(5): E217–E226.

Zhao, Y., S. Xu, L. Wang, D. P. Chin, S. Wang, G. Jiang, H. Xia, Y. Zhou, Q. Li, X. Ou, Y. Pang, Y. Song, B. Zhao, H. Zhang, G. He, J. Guo, and Y. Wang. 2012. National survey of drug-resistant tuberculosis in China. New England Journal of Medicine 366(23):2161–2170.

Zignol, M., C. Sismanidis, D. Falzon, P. Glaziou, M. Dara, and K. Floyd. 2013. Multidrug-resistant tuberculosis in children: Evidence from global surveillance. European Respiratory Journal 42(3):701–707.

Suggested Citation:"References." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×

This page intentionally left blank.

Suggested Citation:"References." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×
Page 143
Suggested Citation:"References." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×
Page 144
Suggested Citation:"References." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×
Page 145
Suggested Citation:"References." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×
Page 146
Suggested Citation:"References." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×
Page 147
Suggested Citation:"References." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×
Page 148
Suggested Citation:"References." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×
Page 149
Suggested Citation:"References." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×
Page 150
Next: Appendix A: Workshop Agenda »
The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences Get This Book
×
Buy Paperback | $48.00 Buy Ebook | $38.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Multidrug-resistant tuberculosis (TB) is caused by bacteria resistant to isoniazid and rifampicin, the two most effective first-line anti-TB drugs, originally developed and introduced in the 1950 and 1960s. Since 2008, the Forum on Drug Discovery, Development, and Translation of the Institute of Medicine has hosted or co-hosted six domestic and international workshops addressing the global crisis of drug-resistant TB, with special attention to the BRICS countries - Brazil, Russia, India, China, and South Africa.

The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS is the summary of a workshop convened to address the current status of drug-resistant TB globally and in China. This report considers lessons learned from high burden countries; highlights global challenges to controlling the spread of drug-resistant strains; and discusses innovative strategies to advance and harmonize local and international efforts to prevent and treat drug-resistant TB. Additionally, the report examines the problem of MDR TB and emergent TB strains that are potentially untreatable with drugs available and considers the critical leadership role of the BRICS countries in addressing the threats and opportunities in drug-resistant TB.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!